8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 15, 2004

               Shire Pharmaceuticals Group plc               
(Exact name of registrant as specified in its charter)

                           England and Wales                           
(State or other jurisdiction of incorporation)

0-29630
(Commission File Number) 98-0359573
(IRS Employer Identification No.)

Hampshire International Business Park, Chineham, Basingstoke,
                           Hampshire RG24 8EP England                           
(Address of principal executive offices)    (Zip code)

Registrant's telephone number, including area code         44 1256 894 000

______________________________________________________________________
(Former name or former address, if changed since last report)

Item 5. Other Events

     Shire Pharmaceuticals Group plc has issued the press release attached as Exhibit 99.1 and which is incorporated by reference herein.

Item 7. Financial Statements and Exhibits

           (c) Exhibits. The following exhibit is filed herewith:
99.1         Press Release dated April 15, 2004

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PHARMACEUTICALS GROUP PLC
By:	/s/ A C Russell                 Name: Angus Russell Title:   Group Finance Director

Dated: April 15, 2004

EXHIBIT INDEX

Number    Description
99.1          Press Release dated April 15, 2004

EX-99.1

EXHIBIT 99.1

Shire Pharmaceuticals Group plc
Hampshire International Business Park,
Chineham, Basingstoke RG24 8EP UK
Tel +44 1256 894000  Fax +44 1256 894708
http://www.shire.com

FIRST QUARTER 2004 RESULTS DATE NOTIFICATION – 29^th April

Basingstoke, UK – 15 April 2004 – Shire Pharmaceuticals Group plc (LSE: SHP, NASDAQ: SHPGY; TSX: SHQ) will announce first quarter 2004 earnings on Thursday, 29 April 2004.

Results announcement time:	12:00 BST / 07:00 EST
Conference call time:	13:30 BST / 08:30 EST

Live conference call:
Matthew Emmens, Chief Executive Officer; Angus Russell, Chief Financial Officer and Wilson Totten, Chief Scientific Officer will host the live conference call at 13:30 BST/8:30 EST.

Please RSVP claire.rowell@fd.com (T: +44 (0)20 7269 7285).

The details of the live conference call are as follows:

UK dial in	+44 (0) 1452 569393
US / Canada dial	+1 866 434 1089
in
Password	Shire

Live Webcast:
The call will also be available live over the Internet via audio webcast, accessible through www.shire.com in the investor relations section. A slide presentation to accompany the call will also be available on the Shire website.

Replay:
A replay of the presentation will be available for 1 week. Details are as follows:

UK dial in	+44 (0) 1452 550000
Pin code	1261750#
US dial in	+1 866 247 4222
Pin code	1261750#
Webcast Replay	www.shire.com, in the investor relations section

If you have any problems accessing this, please contact: Souheil Salah on: +44 (0) 1256 894160

End

For further information please contact:

Souheil Salah – Investor Relations             +44 (0)1256 894 160

Notes to editors

Shire Pharmaceuticals Group plc

Shire Pharmaceuticals Group plc (Shire) is a global specialty pharmaceutical company with a strategic focus on meeting the needs of the specialist physician and currently focuses on developing projects and marketing products in the areas of central nervous system (CNS), gastrointestinal (GI), and renal diseases. Shire has operations in the world’s key pharmaceutical markets (US, Canada, UK, France, Italy, Spain and Germany) as well as a specialist drug delivery unit in the US.

For further information on Shire, please visit the Company’s website: www.shire.com.